IO Combinations in First-line Advanced HCC: Current Evidence and Ongoing Trials

Download this slideset from Ghassan K. Abou-Alfa, MD, MBA, to see the latest data on first-line immunotherapy treatment options for patients with advanced hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, MBA
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 598 KB
Released: October 14, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Experts describe key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH
Program Director
Yelena Y. Janjigian, MD Sandip P. Patel, MD
Released: June 8, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Michael J. Pishvaian, MD, PhD Released: June 3, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

John L. Marshall, MD Released: June 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings